Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.39 |
| ▸ | TOP1 | P11387 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18994197 | 1.00 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL16745479 | 1.00 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL20097499 | 1.00 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL17775556 | 1.00 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL16745470 | 1.00 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL23250849 | 1.00 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL16745469 | 1.00 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL14147723 | 1.00 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL28495296 | 0.97 | TDP1 (0.63) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL28495295 | 0.97 | TDP1 (0.63) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920082-B2 | Water-soluble complexing agents and corresponding lanthanide complexes | CISBO BIOASSAYS (FR) | 2018-03-20 | — | — | US | disclosed |
| US-20150361116-A1 | NOVEL WATER-SOLUBLE COMPLEXING AGENTS AND CORRESPONDING LANTHANIDE COMPLEXES | CISBIO BIOASSAYS (FR) | 2015-12-17 | — | — | US | disclosed |
| WO-2014111661-A1 | NOVEL WATER-SOLUBLE COMPLEXING AGENTS AND CORRESPONDING LANTHANIDE COMPLEXES | CISBIO BIOASSAYS (FR) | 2014-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361116-A1 | NOVEL WATER-SOLUBLE COMPLEXING AGENTS AND CORRESPONDING LANTHANIDE COMPLEXES | RCC1, CLIC1, RCC2 | LMNA 381/4885L3MBTL1 2133/4885TDP1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.